Literature DB >> 14517841

Identification of novel proteins associated with hepatocellular carcinomas using protein microarrays.

Andrea Tannapfel1, Kathrin Anhalt, Philip Häusermann, Florian Sommerer, Markus Benicke, Dirk Uhlmann, Helmut Witzigmann, Johann Hauss, Christian Wittekind.   

Abstract

Characterization of the protein profiles expressed by hepatocellular carcinomas (HCCs) may identify the genes involved in hepatocellular carcinogenesis and offers the possibility of elucidating clinical biomarkers. In an effort to discover such proteins and pathways that are deregulated in hepatocellular carcinogenesis, cellular proteomes of matched normal liver cells and carcinoma were analysed by tissue microdissection and protein microarrays. Using protein microarrays made up of 83 different antibodies, it was possible to monitor alterations of the protein levels in HCC and non-neoplastic liver tissue. Further analysis of altered proteins was performed using western blot analysis and tissue microarrays (TMAs) containing 210 HCC specimens and corresponding liver tissue. The protein microarray approach revealed differential expression between HCC and normal liver of 32 of the 83 proteins examined: 21 of these were up-regulated and 11 down-regulated. IGF (insulin growth factor) II, ADAM (a disintegrin and metalloproteases) 9, STAT (signal transducers and activators of transcription) 3, SOCS (suppressors of cytokine signalling) 3, and cyclin D1 were significantly up-regulated and collagen I, SMAD 4, FHIT (fragile histidine triad), and SOCS1 were down-regulated. The differential expression of these proteins was confirmed using western blot analysis and TMAs. Correlation of differentially regulated proteins with clinico-pathological data showed that cyclin D1 and SOCS1 were associated with tumour prognosis in univariate analysis, but not multivariate analysis. These data indicate that the development of an array-based approach for the determination of protein profiles in HCC may facilitate the identification of new proteins associated with carcinogenesis or prognosis. Copyright 2003 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14517841     DOI: 10.1002/path.1420

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

Review 1.  Personalized medicine and development of targeted therapies: The upcoming challenge for diagnostic molecular pathology. A review.

Authors:  Manfred Dietel; Christine Sers
Journal:  Virchows Arch       Date:  2006-04-22       Impact factor: 4.064

Review 2.  [Methylation and other new concepts for the origin of hepatocellular carcinoma].

Authors:  A Tannapfel
Journal:  Pathologe       Date:  2006-07       Impact factor: 1.011

3.  Immunoprofiles of 11 biomarkers using tissue microarrays identify prognostic subgroups in colorectal cancer.

Authors:  Thomas Knösel; Anna Emde; Karsten Schlüns; Yuan Chen; Karsten Jürchott; Matthias Krause; Manfred Dietel; Iver Petersen
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

4.  High sensitivity automated multiplexed immunoassays using photonic crystal enhanced fluorescence microfluidic system.

Authors:  Yafang Tan; Tiantian Tang; Haisheng Xu; Chenqi Zhu; Brian T Cunningham
Journal:  Biosens Bioelectron       Date:  2015-05-19       Impact factor: 10.618

Review 5.  Microarrays, antiobesity and the liver.

Authors:  Fernando Castro-Chávez
Journal:  Ann Hepatol       Date:  2004 Oct-Dec       Impact factor: 2.400

6.  Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC.

Authors:  Y Tian; B Guo; H Jia; K Ji; Y Sun; Y Li; T Zhao; L Gao; Y Meng; D V Kalvakolanu; D J Kopecko; X Zhao; L Zhang; D Xu
Journal:  Cancer Gene Ther       Date:  2012-05-04       Impact factor: 5.987

7.  HDGF and ADAM9 are novel molecular staging biomarkers, prognostic biomarkers and predictive biomarkers for adjuvant chemotherapy in surgically resected stage I non-small cell lung cancer.

Authors:  Jun Zhang; Ning Chen; Juan Qi; Baosen Zhou; Xueshan Qiu
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-27       Impact factor: 4.553

Review 8.  The pleiotropic roles of ADAM9 in the biology of solid tumors.

Authors:  Victor O Oria; Paul Lopatta; Oliver Schilling
Journal:  Cell Mol Life Sci       Date:  2018-03-17       Impact factor: 9.261

9.  Fragile histidine triad gene alterations are not essential for hepatocellular carcinoma development in South Korea.

Authors:  Chang-Woo Nam; Jung-Woo Shin; Neung-Hwa Park
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

10.  Role of transforming growth factor-beta1-smad signal transduction pathway in patients with hepatocellular carcinoma.

Authors:  Guo-Zhong Ji; Xue-Hao Wang; Lin Miao; Zheng Liu; Ping Zhang; Fa-Ming Zhang; Jian-Bing Yang
Journal:  World J Gastroenterol       Date:  2006-01-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.